Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML)
Year: 2013
Type: article
Source: Blood
Authors: Michael W. Deininger, Neil P. Shah, Jorge E. Cortes, Dong-Wook Kim, Franck E. Nicolini, Moshe Talpaz, Michele Baccarani, Martin C Muller, Jin Li, Stephanie Lustgarten, Tim Clackson, Christopher D Turner, Frank G Haluska, Graeme Hodgson, Victor M. Rivera, Francois Guilhot, John M Goldman, Hagop M. Kantarjian, Simona Soverini, Andreas Hochhaus, Timothy P. Hughes, Susan Branford
Institutions: University of Utah, Huntsman Cancer Institute, University of California, San Francisco, The University of Texas MD Anderson Cancer Center, Catholic University of Korea, Hôpital Lyon Sud, University of Michigan, University of Bologna, University Medical Centre Mannheim, Medizinische Fakultät Mannheim, ARIAD Pharmaceuticals (United States), Inserm, Centre Hospitalier Universitaire de Poitiers, Imperial College London, Jena University Hospital, South Australia Pathology, South Australian Health and Medical Research Institute, The University of Adelaide, Centre for Cancer Biology
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2347166123